Two More IO Drugs Coming In China As Hengrui, Lee’s File NDAs

Increasingly Crowded Field

The latest immuno-oncology newcomers from Lee’s Pharma and Jiangsu Hengrui will further choke an already crowded field in China if they are approved following recent filings.

two new PD-L1 filing in China — Chinese biopharma companies' craving for PD-1/L1 approvals still growing • Source: Alamy

Even more immuno-oncology antibodies may be coming in China as two new drug applications from domestic biopharmaceutical companies have been filed with the national regulatory agency.

Hong Kong-listed Lee's Pharmaceutical Holdings Limited said in a stock market disclosure on 27 October that its NDA for...